Cytokine regulation of the acute-phase protein levels in multiple myeloma

European Journal of Clinical Investigation

Volumn 28, Issue 8, 1998, Pages 679-686

  Biro L ^a,f   Domjan Gy ^b,c   Falus, A ^c   Jakab, L ^c   Cseh, K ^c   Kalabay, L ^c   Tarkovacs G ^c   Tresch, J ^c   Malle, E ^d   Kramer, J ^a,e,f   Prohaszka Z ^c,e   Jako J ^b,c   Fust G ^c,e   Csaszar A ^c  

^a National Institute of Haematology and Immunology Budapest   (Hungary)

^b 1st Clinic of Internal Medicine   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d UNIVERSITY OF GRAZ   (Austria)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^f SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Acute phase proteins; Acute phase response; Complement; Multiple myeloma; Regulation

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA INTERFERON; CARMUSTINE; COMPLEMENT; CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6; MELPHALAN; PREDNISOLONE; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ACUTE-PHASE PROTEINS; ACUTE-PHASE REACTION; AGED; BLOOD PROTEINS; COMPLEMENT C5; COMPLEMENT C8; COMPLEMENT C9; CYTOKINES; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSFERRIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15144353142     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00333.x     Document Type: Article

References (48)

1. Castell JV, Andus T, Kunz D, Heinrich PC. Interleukin-6. The major regulator of acute-phase protein synthesis in man and rat. Ann NY Acad Sci 1989; 557: 87-99.
2. Castell JV, Gomez-Lechnon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase protein response of human hepatocytes: regulation of acute-phase proteins synthesis by interleukin-6. Hepatology 1990; 12: 1179-86.
3. Falus A, Rokita H, Walcz E, Brozik M, Hidvégi T, Merétey K. Hormonal regulation of complement biosynthesis in human cell lines. - II. Upregulation of the biosynthesis of complement components C3, factor B and C1 inhibitor by interleukin-6 and interleukin-1 in human hepatoma cell line. Mol Immunol 1990; 27: 197-201.
4. Zuraw BL, Lotz M. Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte stimulating factors interleukin 6 and interferon gamma. J Biol Chem 1990; 265: 12664-70.
5. Katz U, Guterman M, Lahat E. Regulation of synthesis of complement proteins in Hep2 cells. Clin Immunol Immunopathol 1993; 67: 117-23.
6. Weber J, Yang JC, Topolian SL et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993; 11: 499-506.
7. Van Gameran MM, Willemse PBH, Mulder MH. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994; 38: 119-26.
8. Banks RE, Forbes MA, Storr M et al. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 1995; 102: 217-23.
9. Timmerman JJ, Verweij VL, van Gijsslijk-Jansse DJ, van der Woude FJ, van Es LA, Daha MR. Cytokine-regulated production of the major histocompatibility complex class-III-encoded complement proteins factor B and C4 by human glomerular mesangial cells. Hum Immunol 1995; 43: 19-28.
10. Andoh A, Fujiyama Y, Bamba T, Hosoda S. Differential cytokine regulation of complement C3, C4, and factor B synthesis in human intestinal epithelial cell line, Caco-2. J Immunol 1993; 151: 4239-47.
11. Swaak AJM, Lienard D, Schraffordt Koops H, Lejeune FJ, Eggermont AM. Effects of recombinant tumour necrosis factor (rTNF-alpha) in cancer. Observations of the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF alpha administration in isolated limb perfusion. Eur J Clin Invest 1993; 23: 812-8.
12. Ramadori G, Sipe JD, Dinarello CA, Mizel SB, Colten HR. Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med 1985; 162: 930-42.
13. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
14. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994; 15: 81-8.
15. Nachbaur DM, Herold M, Maneschg A, Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 1991; 62: 54-8.
16. Solary E, Guiguet M, Zeller V et al. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumor cell mass parameters in multiple myeloma. Am J Hematol 1992; 39: 163-71.
17. Tienhaara A, Pulkii K, Manila K, Irjala K, Pelleniemi TT. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol 1994; 86: 391-3.
18. Pelleniemi TT, Irjala K, Manila K et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995; 85: 765-71.
19. Pisa P, Stenke L, Barnell P, Hansson M, Hast R. Tumor necrosis factor-alpha and interferon-gamma in serum of multiple myeloma patients. Anticancer Res 1990; 10: 817-20.
20. Kawano M, Kuramoto A, Hirano T, Kishimoto T. Cytokines as automne growth factors in malignancies. Cancer Surv 1989; 8: 905-19.
21. Lokhorst HM, Lamme T, De Smet M et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994; 84: 2269-77.
22. Bataille R, Harosseau JL. Multiple myeloma. New Engl J Med 1997; 336: 1658-64.
23. Merlini G, Perfetti V, Gobbi PG et al. Acute phase proteins and prognosis of multiple myeloma. Br J Haematol 1993; 83: 595-601.
24. Merico F, Begui L, Gregoretti MG et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 1993; 92: 27-31.
25. Volanakis JE. Transcriptional regulation of complement genes. Annu Rev Immmunol 1995; 13: 277-305.
26. Spath GF, Ramadori G, Rittner S, Schneider PM. Expression of the complement C8 genes during interleukin-6-mediated in vitro induction of the acute-phase response. Exp Clin Immunogenet 1995; 12: 53-60.
27. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-54.
28. Aarden LA, De Groot ER, Schaap OL, Lansdorp PJ. Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987; 17: 1411-6.
29. Helle M, Boeije L, De Groot E, De Vos A, Aarden L. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991; 138: 47-55.
30. Cseh K, Beutler B. Alternative cleavage of the cachectin/ tumor necrosis factor propeptide results in a larger, inactive form of secreted protein. J Biol Chem 1989; 264: 16256-60.
31. Kalabay L, Cseh K, Benedek Sz et al. Serum α2-HS-glycoprotein concentration in patients with hematological malignancies: a follow up study. Ann Hematol 1991; 63: 264-9.
32. Jakab L, Fekete S, Cseh K, Benedek Sz. Serum proteins in processes associated with an increase in the monoclonal and polyclonal immunoglobulin levels. Acta Med Acad Sci Hung 1980; 37: 261-6.
33. Füst G, Schmidt B, Varga L. Clinical significance of hypercomplementemia. In: Erdei A, ed. New Aspects of Complement Structure and Function. Austin-Georgetown: Landes, 1994: 161-71.
34. Gabay C, Roux-Lombart P, De Moerloose P, Dayer JM, Vischert T, Guernie PA. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993; 20: 815-21.
35. Gross V, Andus T, Caesar I, Roth M, Schölmerich F. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514-9.
36. Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute phase protein response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219: 323-4.
37. McMillan DC, Graham AF, Smith J, Wotherspoon HA, Fearon KC, McArdle CS. Interleukin-6, neutrophilia and the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol 1994; 20: 151-4.
38. Gallo O, Gori AM, Attanasio M, Martini F et al. Interleukin-6 and acute-phase proteins in head and neck cancer. Eur Arch Othorhinolaryngol 1995; 252: 159-62.
39. Gauldie J, Richards C, Harnish D. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulatory factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84: 7251-6.
40. Ihle JN, Kerr IM. Jaks and Stats in signaling by the cytokine receptor superfamily. TIG 1995; 11: 69-74.
41. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243-54.
42. Buompas DT, Paliogianni J, Anastassion ED, Balow JE. Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin Exp Rheumatol 1991; 9: 413-23.
43. Snyers L, De Wit L, Content J. Glucocorticoid up-regulation of high affinity interleukin 6 receptors on human epithelial cells. Proc Natl Acad Sci USA 1990; 87: 2838-42.
44. Wiedermann D, Wiedermann B, Cidl V, Kodukova V. Individual serum proteins and acute phase reactants in monoclonal immunglobulinopathies (a study in patients with IgG myeloma). Neoplasma 1978; 25: 189-96.
45. Daveau M, Davrinche C, Julen N, Hiron M, Arnaud P, Lebreton JP. The synthesis of human α-2-HS-glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett 1988; 241: 191-4.
46. Daveau M, Davrinche C, Djeleassi N et al. Partial hepatectomy and mediators of inflammation decrease the expression of liver α2-HS glycoprotein gene in rats. FEBS Lett 1990; 273: 79-81.
47. Akhoundi C, Amiot M, Auberger P, Le Cam A, Rossil B. Insulin and interleukin 1 differentially regulate pp. 63, an acute phase phosphoprotein in hepatoma cell line. J Biol Chem 1994; 269: 15925-30.
48. Lu ZY, Brailly H, Wijdenes J, Bataille R, Ross JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction efficacy anti-IL-6 treatments. Blood 1995; 86: 3123-31.